HIGHFDA DRUG

Curosurf 240 mg Poractant Alfa Recalled for Sterility Concerns (2026)

Chiesi USA recalled 7,235 Curosurf vials distributed nationwide to hospitals and clinics. The recall cites a lack of assurance of sterility. Healthcare providers should stop using the product immediately and contact Chiesi USA for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 17, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 17, 2026
Hazard Level
HIGH
Brands
CUROSURF, Chiesi USA, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
INFANTS, GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
CUROSURF, Chiesi USA, Inc.
Product type
Curosurf (poractant alfa) Intratracheal Suspension 240 mg, 3L Single-Dose Vial
Model numbers
Lot #: 1213748, Exp. Date 09/2026, 1215076, 1215077, Exp. Date 10/26.
UPC codes
10122-510, 10122-510-03, 10122-510-01
Sizes
3L
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 17, 2026

  2. Reported by FDA DRUG

    April 1, 2026

  3. RecallRadar source check

    April 8, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Lack of Assurance of Sterility

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Chiesi USA, Inc. or your healthcare provider for guidance. Notification method: Letter

About This Product

Curosurf is a neonatal surfactant used to treat respiratory distress in preterm infants. It is delivered intratracheally in a hospital setting.

Why This Is Dangerous

Lack of sterility could introduce microbial contamination, potentially causing infection in vulnerable neonates.

Industry Context

This recall is not indicated as part of a broader industry pattern at this time.

Real-World Impact

Hospitals must halt use of affected vials and coordinate with distributors for replacement; potential patient risk if contaminated product is administered.

Practical Guidance

How to identify if yours is affected

  1. Verify NDC 10122-510-03 on the product label.
  2. Check lot numbers 1213748, 1215076, 1215077.
  3. Confirm expiration dates 09/2026 or 10/2026.

Where to find product info

NDC and lot numbers are printed on vial labels and packaging.

What timeline to expect

Replacements or credits are typically coordinated within hospital supply chains over several weeks; patient care adjustments may occur during this时间.

If the manufacturer is unresponsive

  • Escalate to hospital procurement leadership
  • Contact Chiesi USA’s recall notice for escalation procedures
  • File a report with the hospital's CPS/CQA department

How to prevent similar issues

  • Source neonatal surfactants only through approved hospital distributors
  • Verify sterility and batch information before administration
  • Maintain updated recall contact lists for suppliers

Documentation advice

Keep a copy of the recall notice, purchase records, lot numbers, and all correspondences with the supplier.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Curosurf (poractant alfa) Intratracheal Suspension, 240 mg, 3L Single-Dose Vial, Rx only. NDC: 10122-510-03. Distributed nationwide to healthcare facilities. Quantity recalled: 7,235 vials. Lot numbers: 1213748, 1215076, 1215077. Expiration dates observed: 09/2026 and 10/2026. Sold by: Nationwide healthcare distribution. Manufacturer: Chiesi USA, Inc., Cary, NC.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Exp. dates 09/2026 and 10/2026

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
INFANTSGENERAL
Injury Types
POISONINGOTHER

Product Classification

Product TypeCurosurf (poractant alfa) Intratracheal Suspension 240 mg, 3L Single-Dose Vial
Sold At
Multiple Retailers

Product Details

Model Numbers
Lot #: 1213748
Exp. Date 09/2026
1215076
1215077
Exp. Date 10/26.
UPC Codes
10122-510
10122-510-03
10122-510-01
Affected States
ALL
Report Date
April 1, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more